ArticleiGIE : innovation, investigation and insights2024
EUS-guided pancreatic duct drainage: a single-center observational study.
Article in iGIE : innovation, investigation and insights, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Pancreatic duct obstruction can cause pain and atrophy of the pancreatic parenchyma. Endoscopic drainage is the first-line treatment, usually by means of ERCP. However, in some patients, the classic transpapillary approach cannot be performed owing to anatomic inability to access the papilla, rupture of the main pancreatic duct, intracanal stones that cannot be crossed, or tight stenosis of the main pancreatic duct due to extrinsic compression by parenchymal calcifications. EUS-guided pancreatic duct drainage is an efficient and minimally invasive therapeutic alternative for these patients. We aimed to evaluate clinical success of EUS-guided pancreatic duct drainage in our center. Methods: Data of patients who underwent EUS-guided pancreatic duct drainage in our center from 2016 to 2022 were retrospectively reviewed. Clinical success was defined as pain ≤2 on the pain visual analog scale (VAS; 0-10) and no recurrence of obstructive pancreatitis after successful stent placement. If the indication for the procedure was chronic pancreatitis with painless weight loss, then clinical success was defined as weight stabilization or weight regain after the procedure. Results: Forty-six patients (mean age 58 years, 69.6% male) were included. One indication of EUS-guided pancreatic duct drainage was chronic pancreatitis in 69.6% of patients (78.1% due to alcohol abuse). Other indications included postoperative adverse events, rupture of pancreatic duct, and pancreatic cancer. Technical success was achieved in 93.5% of patients. Forty patients had pancreaticogastrostomy and 3 patients pancreaticoduodenostomy. The mean hospital stay was 2 days. Clinical success was 93% in patients who achieved technical success. Remaining pain (VAS >2) occurred in 9.3% of patients and obstructive pancreatitis recurrence in 6.9%. Adverse events occurred in 5 patients (11.6%). Eighteen stent dysfunctions, 16 stent migrations, and 2 stent obstructions were observed. No patients died from the procedure. Conclusions: EUS-guided pancreatic duct drainage showed a high clinical success rate. It is therefore a good minimally invasive alternative to avoid pancreatic surgery in patients with symptomatic pancreatic duct stenosis of benign or malignant etiology who failed ERCP.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.